Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring

NCT04037254 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
22
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

NRG Oncology

Collaborators